Duvelisib (IPI-145, INK1197)
Duvelisib (IPI-145, INK1197) structure
|
Common Name | Duvelisib (IPI-145, INK1197) | ||
|---|---|---|---|---|
| CAS Number | 1201438-56-3 | Molecular Weight | 416.863 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C22H17ClN6O | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Duvelisib (IPI-145, INK1197)Duvelisib is a selectivite p100δ inhibitor with IC50 of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively. |
| Name | 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one |
|---|---|
| Synonym | More Synonyms |
| Description | Duvelisib is a selectivite p100δ inhibitor with IC50 of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively. |
|---|---|
| Related Catalog | |
| Target |
p110δ:2.5 nM (IC50) p110γ:27.4 nM (IC50) p110β:85 nM (IC50) p110α:1602 nM (IC50) |
| In Vitro | PI3Kδ and PI3Kγ inhibition with IPI-145 has anti-proliferative activity in primary AML cells by inhibiting the activity of AKT and MAPK. Pre-treatment of AML cells with IPI-145 inhibits both adhesion and migration of AML blasts to bone marrow stromal cells[1]. |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Molecular Formula | C22H17ClN6O |
| Molecular Weight | 416.863 |
| Exact Mass | 416.115234 |
| PSA | 88.49000 |
| LogP | 4.60 |
| Index of Refraction | 1.757 |
| Storage condition | -20°C |
|
~94%
Duvelisib (IPI-... CAS#:1201438-56-3 |
| Literature: Ren, Pingda; Martin, Michael; Isbester, Paul; Lane, Benjamin S.; Kropp, Jason Patent: US2012/184568 A1, 2012 ; Location in patent: Page/Page column 83-84 ; |
|
~%
Duvelisib (IPI-... CAS#:1201438-56-3 |
| Literature: WO2011/146882 A1, ; WO 2011/146882 A1 |
|
~%
Duvelisib (IPI-... CAS#:1201438-56-3 |
| Literature: WO2011/146882 A1, ; WO 2011/146882 A1 |
|
~%
Duvelisib (IPI-... CAS#:1201438-56-3 |
| Literature: WO2011/146882 A1, ; WO 2011/146882 A1 |
|
~%
Duvelisib (IPI-... CAS#:1201438-56-3 |
| Literature: US2012/184568 A1, ; |
|
~%
Duvelisib (IPI-... CAS#:1201438-56-3 |
| Literature: US2012/184568 A1, ; |
|
~%
Duvelisib (IPI-... CAS#:1201438-56-3 |
| Literature: WO2011/146882 A1, ; WO 2011/146882 A1 |
|
~%
Duvelisib (IPI-... CAS#:1201438-56-3 |
| Literature: US2012/184568 A1, ; |
|
~%
Duvelisib (IPI-... CAS#:1201438-56-3 |
| Literature: US2012/184568 A1, ; |
![Carbamic acid, N-[(1S)-3-[3-chloro-2-[(phenylamino)carbonyl]phenyl]-1-methyl-2-oxopropyl]-, 1,1-dimethylethyl ester structure](https://image.chemsrc.com/caspic/211/1386861-47-7.png)
![3-[(1S)-1-Aminoethyl]-8-chloro-2-phenyl-1(2H)-isoquinolinone structure](https://image.chemsrc.com/caspic/252/1350643-72-9.png)
| 8-Chloro-2-phenyl-3-[(1S)-1-(3H-purin-6-ylamino)ethyl]-1(2H)-isoquinolinone |
| IPI-145 |
| 1(2H)-Isoquinolinone, 8-chloro-2-phenyl-3-[(1S)-1-(9H-purin-6-ylamino)ethyl]- |
| UNII-610V23S0JI |
| INK1197 |
| INK-1197 |
| duvelisib |